文献速递胸部病理细胞病理与分子病理

INSM1在肺肿瘤中的诊断价值及与现有神经内分泌标志物的比较

Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers.
PubMed 文献 · Arch Pathol Lab Med · 2020-01-01

该研究对54例肺神经内分泌肿瘤和632例非小细胞肺癌进行INSM1、CD56、嗜铬粒蛋白A和突触素染色,并分析419例肺转移瘤的INSM1表达及文献数据。

要点

  • INSM1在肺神经内分泌肿瘤中阳性率72%,非小细胞肺癌仅1%。
  • CD56与INSM1和/或突触素联合是确认肺高级别神经内分泌肿瘤的首选。
  • INSM1基因表达与神经内分泌组织学明确相关。

核心结论

  • INSM1作为肺病理神经内分泌标志物具有诊断价值。
  • CD56联合INSM1和/或突触素应作为确认肺高级别神经内分泌肿瘤的首选。
  • INSM1基因表达可用于预测神经内分泌肿瘤组织学。

研究设计与样本

  • 54例肺神经内分泌肿瘤和632例非小细胞肺癌进行INSM1、CD56、嗜铬粒蛋白A和突触素染色。
  • 部分样本有基因表达数据可供分析。
  • 419例肺转移瘤进行INSM1染色。
  • 文献检索纳入过去15年39项关于肺癌神经内分泌标志物的研究,其中7项包含INSM1数据。

主要发现

  • INSM1阳性:54例神经内分泌肿瘤中39例(72%),623例非小细胞肺癌中6例(1%)。
  • CD56阳性:54例中47例(87%),626例中14例(2%)。
  • 嗜铬粒蛋白A阳性:54例中30例(56%),629例中6例(1%)。
  • 突触素阳性:54例中46例(85%),630例中49例(8%)。
  • 文献分析显示CD56和INSM1在识别高级别肺神经内分泌肿瘤时灵敏度和特异度综合最佳,突触素灵敏度也好。

临床怎么用

  • 病理诊断肺神经内分泌肿瘤时,推荐联合使用CD56与INSM1和/或突触素。
  • INSM1可作为神经内分泌标志物组合的一部分,用于区分神经内分泌肿瘤与非小细胞肺癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: The diagnostic distinction of pulmonary neuroendocrine (NE) tumors from non-small cell lung carcinomas (NSCLCs) is clinically relevant for prognostication and treatment. Diagnosis is based on morphology and immunohistochemical staining. OBJECTIVE.—: To determine the diagnostic value of insulinoma-associated protein 1 (INSM1), in comparison with established NE markers, in pulmonary tumors. DESIGN.—: Fifty-four pulmonary NE tumors and 632 NSCLCs were stained for INSM1, CD56, chromogranin A, and synaptophysin. In a subset, gene expression data were available for analysis. Also, 419 metastases to the lungs were stained for INSM1. A literature search identified 39 additional studies with data on NE markers in lung cancers from the last 15 years. Seven of these included data on INSM1. RESULTS.—: A positive INSM1 staining was seen in 39 of 54 NE tumors (72%) and 6 of 623 NSCLCs (1%). The corresponding numbers were 47 of 54 (87%) and 14 of 626 (2%) for CD56, 30 of 54 (56%) and 6 of 629 (1%) for chromogranin A, and 46 of 54 (85%) and 49 of 630 (8%) for synaptophysin, respectively. Analysis of literature data revealed that CD56 and INSM1 were the best markers for identification of high-grade NE pulmonary tumors when considering both sensitivity and specificity, while synaptophysin also showed good sensitivity. INSM1 gene expression was clearly associated with NE histology. CONCLUSIONS.—: The solid data of both our and previous studies confirm the diagnostic value of INSM1 as a NE marker in pulmonary pathology. The combination of CD56 with INSM1 and/or synaptophysin should be the first-hand choice to confirm pulmonary high-grade NE tumors. INSM1 gene expression could be used to predict NE tumor histology.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Staaf J, Tran L, Söderlund L, et al. Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers. Arch Pathol Lab Med. 2020. PMID: 31913660. doi:10.5858/arpa.2019-0250-OA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。